RECURRENT MALIGNANT SOLID NEOPLASM
Clinical trials for RECURRENT MALIGNANT SOLID NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MALIGNANT SOLID NEOPLASM trials appear
Sign up with your email to follow new studies for RECURRENT MALIGNANT SOLID NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for rare cancers: olaparib targets IDH mutations
Disease control OngoingThis study tests whether the drug olaparib can shrink or slow the growth of advanced solid tumors that have IDH1 or IDH2 gene mutations, including certain brain tumors (gliomas) and bile duct cancers (cholangiocarcinoma). About 89 adults whose cancer has spread or not responded t…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:08 UTC
-
New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
Disease control OngoingThis study tests a drug called ulixertinib in children and teens with advanced solid tumors, lymphoma, or histiocytic disorders that have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or stop the growth of these cancers. About 20 partici…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:06 UTC
-
New hope for kids with tough cancers: targeted pill shows promise
Disease control OngoingThis study tests a drug called ivosidenib (AG-120) in children and young adults (ages 1-21) whose cancers have a specific IDH1 gene change and have come back or not responded to standard treatment. The drug works by blocking a faulty signal that helps cancer grow. The main goal i…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:04 UTC
-
New hope for kids with relapsed cancers: experimental drug elimusertib under study
Disease control OngoingThis study tests an experimental drug called elimusertib in children and young adults whose solid tumors have returned or not responded to standard treatment. The goal is to find the safest dose and see if the drug can shrink tumors by blocking enzymes that cancer cells need to g…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:01 UTC
-
New hope for kids with rare cancers: drug blocks tumor growth
Disease control OngoingThis study tests a daily pill called cabozantinib in children and young adults (up to age 30) with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. The drug works by blocking signals that help tumors grow and form blood vessel…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
Targeted drug shows promise for kids with rare, Hard-to-Treat cancers
Disease control OngoingThis study tested a drug called larotrectinib in children and young adults (ages 1 to 21) with advanced or returning cancers that have a specific genetic change called an NTRK fusion. The goal was to see if the drug could shrink tumors or stop them from growing. The study include…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
New hope for rare childhood cancers: immunotherapy combo shows promise
Disease control OngoingThis study tests two immunotherapy drugs, tiragolumab and atezolizumab, in children and adults whose rare cancers (like certain brain, kidney, and soft tissue tumors) have returned or not responded to treatment. These cancers lack specific genes (SMARCB1 or SMARCA4), making them …
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:52 UTC
-
New cocktail of drugs shows promise for Hard-to-Treat cancers
Disease control TerminatedThis early-stage trial tests a combination of three drugs—ZEN003694, nivolumab, and ipilimumab—in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the combo can shrink or stabilize tumors. About …
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:52 UTC
-
New hope for kids with rare cancers: targeted drug shows promise in early trial
Disease control OngoingThis study tests a drug called selpercatinib (LOXO-292) in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change in the RET gene. The goal is to see if the drug can shrink tumors or stop them from growing. The trial is for patients who…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New hope for kids with rare cancers: targeted drug shows promise in early trial
Disease control OngoingThis study tested a drug called erdafitinib in children and young adults (ages 1 to 21) whose cancers had come back or were not responding to treatment. The drug targets cancers with specific changes in FGFR genes. The main goal was to see if the drug could shrink tumors. About 2…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Targeted drug shows promise for kids with Tough-to-Treat cancers
Disease control OngoingThis study tested the drug ensartinib in 13 children and young adults (ages 1–21) whose cancers had come back or did not respond to treatment and had specific ALK or ROS1 gene changes. The goal was to see if the drug could shrink or stop tumor growth. While the drug targets cance…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New drug cocktail targets Hard-to-Treat cancers in kids and young adults
Disease control OngoingThis early-phase trial tests a combination of three drugs (dasatinib, temsirolimus, and cyclophosphamide) in children and young adults (ages 1 to 21) with advanced solid tumors that have come back or not responded to standard treatment. The main goals are to find the safest dose …
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Experimental combo aims to shrink Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests the safety and best dose of a drug called copanlisib combined with immunotherapy drugs (nivolumab, with or without ipilimumab) in adults with advanced solid tumors or lymphoma that has not responded to standard treatments. The goal is to find a dose t…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
Childhood cancer immunotherapy trial pulled before starting
Disease control TerminatedThis study was designed to test two immunotherapy drugs, nivolumab and ipilimumab, in children and young adults with cancers that returned or didn't respond to treatment and have many genetic mutations. The goal was to see if the combination could shrink tumors or help patients l…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New hope for hard-to-treat cancers? drug targets tumors with unstable genes
Disease control OngoingThis study tests the drug pembrolizumab in 21 adults with advanced solid tumors that have specific gene mutations (BRCA1, BRCA2, POLE, or POLD1). The goal is to see if the drug can shrink or control the cancer. Pembrolizumab is a type of immunotherapy that helps the immune system…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated May 12, 2026 13:39 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New combo therapy targets cancer fatigue in advanced patients
Symptom relief OngoingThis study looks at whether adding a steroid called dexamethasone to a physical activity program can ease severe tiredness in people with advanced cancer. About 99 patients with fatigue lasting at least 2 weeks will take part. The goal is to see if the combination is practical an…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated May 26, 2026 04:03 UTC
-
New hope for cancer fatigue: drug plus lifestyle changes tested
Symptom relief OngoingThis study tests whether a drug called anamorelin, combined with physical activity and nutritional counseling, can ease severe fatigue in people with advanced solid tumors that cannot be cured. About 129 participants will receive the combination for several weeks, and researchers…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated May 26, 2026 04:01 UTC
-
Honest placebo: a sugar pill that might fight cancer fatigue?
Symptom relief OngoingThis study tests whether an open labeled placebo—a pill with no active drug that patients know is a placebo—can reduce severe fatigue in people with advanced cancer. About 100 participants will either receive the placebo or be placed on a waitlist. The goal is to see if simply be…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2, PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated May 26, 2026 03:53 UTC
-
Expert tumor board aims to unlock genetic secrets for advanced cancer patients
Knowledge-focused OngoingThis study looks at whether a special team of doctors and scientists (a genomic tumor board) can help more patients with advanced solid tumors receive treatments that match their cancer's genetic makeup. About 1,284 patients will be involved, and their doctors will either use the…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: NA • Sponsor: SWOG Cancer Research Network • Aim: Knowledge-focused
Last updated May 26, 2026 03:57 UTC
-
Cancer weight loss study seeks to ease hidden toll on patients and families
Knowledge-focused OngoingThis study looks at how often cancer patients in a supportive care clinic experience cachexia (unintentional weight loss and loss of appetite) and the emotional burden it places on both patients and their primary caregivers. Researchers will track weight changes and use questionn…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 26, 2026 03:54 UTC
-
Brain wave study reveals if dying patients can still hear
Knowledge-focused TerminatedThis study uses a brain wave test (EEG) to find out if cancer patients who appear unresponsive in their final days can still hear or feel. Researchers will measure brain activity when sounds or words are played. The goal is to help families and doctors understand what patients ma…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 26, 2026 03:54 UTC
-
Money stress in cancer care: can a navigator ease the burden?
Knowledge-focused OngoingThis study tests a program where a financial navigator helps cancer patients and their partners understand insurance, set up payment plans, and find cost-saving options. The goal is to see if this support reduces financial hardship and improves quality of life. About 331 patients…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: NA • Sponsor: SWOG Cancer Research Network • Aim: Knowledge-focused
Last updated May 22, 2026 14:00 UTC
-
Gene-Guided hope: pediatric MATCH trial aims to outsmart tough childhood cancers
Knowledge-focused OngoingThis study screens children and young adults (ages 1–21) with advanced solid tumors, lymphomas, or related disorders that have come back or not responded to standard therapy. Researchers analyze the genetic makeup of each patient's tumor to find specific mutations that can be tar…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 22, 2026 13:52 UTC
-
Gene test trial aims to outsmart advanced cancers
Knowledge-focused OngoingThis study tests whether analyzing the genes in a patient's tumor can help doctors choose a more effective treatment. Over 6,400 adults with advanced or hard-to-treat cancers (solid tumors, lymphoma, or myeloma) had their tumors genetically screened. Those with specific genetic c…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 22, 2026 13:51 UTC
-
Which method brings palliative care to cancer patients best?
Knowledge-focused OngoingThis study looks at two different ways to provide palliative care—a special type of care that helps with symptoms and stress—to people with advanced cancer and their caregivers. One method uses a virtual learning group, and the other uses one-on-one technical help. The goal is to…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: NA • Sponsor: University of Rochester NCORP Research Base • Aim: Knowledge-focused
Last updated May 20, 2026 11:55 UTC